Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIT225 plus pegylated interferon and ribavirin in treatment-naive chronic hepatitis C
ACTRN12612000828820Phase 2Completed
- Sponsor
- Biotron Ltd
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BIT225 in chronic hepatitis C (CHC), sponsored by Biotron Ltd. Primary endpoint: Safety and tolerability of BIT225 plus pegylated interferon and ribavirin. Started Nov 2010; status: completed.
02
Drugs
BIT225
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on ACTRN12612000828820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000828820.